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Abstract
Alport syndrome is a multisystem disorder including progressive renal disease, senso-
rineural deafness, and eye abnormalities. The high risk of cardiovascular pathology in 
patients with Alport syndrome was also described recently. The syndrome is caused by 
mutations in COL4A3, COL4A4, and COL4A5 genes, which lead to defects in glomeru-
lar filtration barrier and other basement membrane. The diagnosis of Alport syndrome 
should be suspected in patients with glomerular hematuria and with family history of 
renal failure. The severity of the individual symptoms and renal prognosis are variable 
and depend on gene mutation type. The current standard of treatment is the use of 
angiotensin-converting enzyme inhibitors, which delay the progression of renal failure 
in Alport syndrome. The recent knowledge in pathogenesis of disease opens new thera-
peutic perspectives.
Keywords: Alport syndrome, COL4A5, COL4A4, COL4A3, kidney disease, glomerular 
basement membrane, hematuria, albuminuria, proteinuria, renal failure, sensorineural 
deafness, lenticonus, fleck retinopathy, corneal dystrophy, angiotensin-converting 
enzyme inhibitors
1. Introduction
Alport syndrome is the most frequent hereditary glomerulopathy affecting approximately 1 in 
5000–53,000 people. The disease caused by mutations in the COL4A3, COL4A4, and COL4A5 
genes, which encode the α3, α4, and α5 chains of collagen type IV, a component of the base-
ment membrane of the kidney, the eye, and the inner ear. The syndrome includes progressive 
nephropathy, ocular abnormalities, and high-tone sensorineural deafness. Clinical features 
and the prognosis of patients with Alport syndrome are known to depend on mutation type. 
The most frequent X-linked form of Alport syndrome is caused by COL4A5 gene defects and 
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detected in 85% of patients. Autosomal recessive inheritance is found in about 15% of patients; 
it can be caused either by homozygous or compound heterozygous mutations in COL4A3 or 
COL4A4. Patients who harbor only one pathogenic variant either in COL4A3 or COL4A4 gene 
are usually diagnosed with thin basement membrane nephropathy or autosomal dominant 
Alport syndrome. Digenic inheritance pattern of Alport syndrome has also been described. 
Current knowledge and future directions on Alport syndrome will be explored in this review.
2. Alport syndrome: genetic, pathogenesis, clinical presentation, 
prognosis, and treatment
2.1. Genetic and genotype-phenotype correlations in Alport syndrome
Several clinical cases of patients with hereditary familial congenital hemorrhagic nephritis 
were published by Arthur C. Alport in 1927. He was the first to recognize the link between 
nephritis and deafness, and he also noted ocular changes in one of these patients [1].
Alport syndrome (AS) is a multisystem disorder including progressive renal disease, sensori-
neural deafness, and eye abnormalities.
Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes, which 
encode the α3, α4, and α5 chains of collagen type IV, a component of the glomerular basement 
membrane (GBM) in the kidney.
COL4A5 gene is located on chromosome X. More than 2300 COL4A5 variants have been 
described to date [2]. Among the pathogenic variants, about 41% are missense mutations 
(with overwhelming majority of them being substitutions of glycine in the Gly-Xaa-Yaa triplet 
of the collagenous domain) which are the most frequent, followed by frameshift, splice site 
mutations, larger copy number variations, and nonsense mutations [3].
The COL4A3 and COL4A4 genes are located on chromosome 2 and share the same promoter 
(they are transcribed in opposite directions). Among COL4A3 and COL4A4 mutations, the 
distribution of mutation types is similar, in particular, glycine substitutions and missense 
mutations of other types still dominate. Incidence of pathogenic variants in the two genes is 
similar [4].
The abovementioned genes are known to have no mutation hotspots; however, some popula-
tion-specific founder mutations have been described, e.g., COL4A5 p.Leu649Arg mutation in 
the US [5], COL4A5 p.Gly624Asp mutation in the Slovenia, Hungary, and Greece [6–8], and 
deletion of exons 2–36 of COL4A5 in French Polynesia [9].
The most frequent X-linked form of AS is caused by COL4A5 gene defects and detected 
in 85% of patients [10] (80% according to Kashtan [11]). It is dominant and more severe in 
males, whereas in females, penetrance depends on X chromosome inactivation pattern [12]. 
Patients demonstrate end-stage renal disease (ESRD) at the age of 8–60 years and usually have 
microhematuria with macrohematuria episodes from childhood [13]. About 80% of affected 
families demonstrate sensorineural hearing loss (at least in some patients) and about 50% are 
characterized by ocular abnormalities [13].
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Autosomal recessive inheritance is found in about 15% of patients with their clinical course 
and ultrastructural changes being similar to those in X-linked form [14]. It can be caused 
either by homozygous or compound heterozygous mutations in COL4A3 or COL4A4 [15, 16].
Patients who harbor only one pathogenic variant either in COL4A3 or COL4A4 gene are usu-
ally diagnosed with thin basement membrane nephropathy (TBMN): benign familial hema-
turia not progressing to ESRD. It is still disputable if patients bearing only one pathogenic 
variant in either COL4A3 or COL4A4 gene who suffer from hematuria, lack hearing or ocular 
abnormalities, and potentially can develop ESRD in late age should be categorized to autoso-
mal dominant AS or TBMN [17].
Digenic inheritance pattern of AS has also been described, which can be caused by two muta-
tions in COL4A3 and COL4A4 genes each (either on the same chromosome or on homologous 
chromosomes) as well as by a combination of two mutations in COL4A5 and COL4A3 or 
COL4A4 gene [18].
AS prognosis is known to depend on the mutation type. Associations have been shown both 
in males with X-linked inheritance and in autosomal recessive form (both sexes). Associations 
of genotype and phenotype have been extensively studied for the following conditions: age at 
onset of ESRD, hearing loss, and ocular abnormalities.
The expected ESRD age is similar for the two types of AS and comprises 23–25 years, exclud-
ing females with X-linked AS [4]. The risk of ESRD development in patients with X-linked AS 
by the age of 30 years is 70% in males, whereas only 5% in females; by the age of 40 years: 90 
and 10%, respectively [19].
Phenotypic and clinical features in AS are known to depend on mutation type. Among patients 
with COL4A5 variants, in males, the risk of development of ESRD by 30 years of age is the 
highest for subjects bearing “severe” mutations (nonsense, frameshift mutations, and multi-
exon deletions): 90%; lower for subjects bearing splice site variants: 70%; the lowest for patients 
bearing missense variants: 50% [19]. In females, there is no statistically significant difference 
neither for age at onset of ESRD nor for presence of hearing or ocular abnormalities [19].
Hearing and ocular abnormalities are also more prevalent in men than in women among 
X-linked AS subjects [20, 21]. Sensorineural hearing loss by the age of 30 is found in 60% of 
male patients with missense mutations compared to 90% of patients with mutations of other 
more severe types (including splice site mutations) [19]. Ocular abnormalities were shown to 
be 2–4 times less prevalent in males harboring pathogenic missense variants [20, 22, 23].
In patients with autosomal recessive AS, mutation type has similar effect on the clinical prog-
nosis [4], which is significant both for women (unlike for X-linked type) and men.
2.2. Pathogenesis of Alport syndrome
Collagen type IV is composed of six different α chains, which assemble into three differ-
ent protomers (α1α1α2, α3α4α5, and α5α5α6) with a tissue-specific distribution [24, 25]. The 
absence of any one of these type IV collagen chains can result in the absence of the whole 
protomer in the GBM, presumably due to an obligatory association of the three chains in 
forming the type IV collagen superstructure [26].
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The heterotrimers are essential for basement membrane structure and function [26]. The 
α3α4α5 protomer in the GBM is only produced by podocytes [27], that is why podocytes 
are a key cell type affected by Alport syndrome pathology. The α1α1α2 heterotrimer is pro-
duced by three cell types in the glomerulus: podocytes, endothelial cells, and mesangial cells 
[27]. The α1α1α2 heterotrimer is ubiquitously distributed in all basement membranes during 
embryogenesis, and then in the process of development, there is a partial replacement of 
α1α1α2 protomer by α3α4α5 heterotrimer in the GBM, lungs, eyes, cochlea, and testes, and 
by the α5α5α6 heterotrimer in skin, smooth muscle cells, kidney’s Bowman capsules, and 
esophagus [28]. This substitution of collagen type IV heterotrimers leads to mechanical stabil-
ity of basement membrane, as the α1α1α2 chains are highly susceptible to endoproteolysis. In 
AS, assembly of the α3α4α5 heterotrimer does not occur, resulting in decreased mechanical 
stability and splitting of the GBM, as well as other tissue-specific pathological changes.
The detailed pathogenetic mechanisms leading to progression of AS are not clear. As the 
GBM is a key component of the filtration barrier, patients with AS develop proteinuria [29] 
as a result of altered podocyte orientation, podocyte effacement, and disruption of slit dia-
phragms. However, interactions between integrins and the laminin α5β2γ1 heterotrimer 
could disrupt the actin cytoskeleton and activate signaling mechanisms that result in an 
increase in matrix metalloproteinase expression and massive accumulation of extracellular 
matrix [25] as well as kidney fibrosis due to fibroblast formation by epithelial-mesenchymal 
transition, initiated as a physiological repair of injury response [30]. Invasion of mesangial 
filopodia may be responsible for deposition of the extracellular molecules in Alport GBM 
[31–33]. These changes could lead to progression of glomerulosclerosis, nephron loss, and 
hypertension. Increasing deposition of extracellular matrix and laminin α5, upregulation of 
matrix metalloproteinase has been shown in the stria vascularis of ear in vivo.
Ultrastructural studies have demonstrated that the fundamental lesion of AS involves the GBM 
[29, 34]. The typical changes of GBM in AS are its thickening, splitting, and fragmentation of 
the lamina densa with formation of a characteristic “basket weave” pattern. The lesions may 
be focal (in the early stages of the disease) or widespread (in the late stages). The thinning or 
irregular appearance of the GBM (an alternation of thickening and thinning) is the prevalent 
changes in children with AS. Diffuse thinning of the GBM as the only morphological changes 
may be observed in 10–20% of patients with Alport syndrome, explaining why patients with 
thin basal membranes may have an unfavorable prognosis. Sometimes, it is possible to see the 
focal ruptures of the GBM and its reparation due to the synthesis of the new material of the 
glomerular basement membrane [35]. The light microscopy changes are not specific and vary 
from the normal renal tissue appearance or minimal glomerular changes in the early stages 
of the disease to focal mesangial proliferation, focal and segmental thickening of the capil-
lary walls, and focal/global glomerulosclerosis in the late stages of the AS. These changes are 
associated with nonspecific tubulointerstitial lesions including foci of lipid-laden foam cells. 
Conventional immunofluorescence detects nothing or only faint or focal deposits of IgG, IgM, 
or complement C3.
The distribution of the different chains of collagen type IV in the basement membranes is 
very important for diagnosis of AS and especially for X-linked transmission’s recognition. 
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Normally, COL4A5 is expressed in the glomerular basement membranes, and the α5(IV) 
chain defect due to COL4A5 mutation (absence or abnormal structure of α5(IV)) impairs 
protomer assembly and the normal collagen IV network formation. Immunohistological 
analysis reveals abnormal distribution of the α5(IV) chain in about two-thirds of patients with 
X-linked AS: in male patients, the α5(IV) antigen is not detected in the glomerular, capsular, 
and distal tubular basement membranes, while in female patients, the α5(IV) antigen has a 
discontinuous distribution. In addition, there is a lack of the α3(IV) and α4(IV) chains which 
participate in the α3α4α5(IV)-α3α4α5(IV) network formation. At the same time, the α1(IV) 
and α2(IV) chains normally confining to the mesangium and the subendothelial aspect of the 
GBM are widely expressed throughout the glomerular basement membrane in these patients. 
This immunohistological picture is typical for the fetal kidneys. But approximately, one-third 
of patients with AS do not have marked changes in the renal expression of α(IV) chains. The 
immunohistochemical picture is usually consistent within the family and correlates with the 
severity of the clinicopathological features of the disease [25, 36].
The distribution of α(IV) chains is also abnormal in skin basement membrane: the absence of 
the α5(IV) and the associated α6(IV) chains from the epidermal basement membrane is typical 
for male patients with X-linked AS and can be detected in about two-thirds of male patients. 
Observation of normal patterns of α5(IV) and α6(IV) localization does not facilitate definitive 
diagnosis in females because of the segmental distribution of the chains.
The peculiar immunohistochemical distribution pattern of α3(IV) to α6(IV) chains is observed 
in the skin and kidneys of most patients with autosomal recessive AS [31, 32, 35] and is char-
acterized by the absence of α3, α4, and α5(IV) chains from the GBM contrasting with the 
persistence of α5(IV) chains in Bowman’s capsules, collecting ducts, and epidermal basement 
membranes. These findings show that in autosomal recessive Alport patients, the expression 
of α5(IV) chains is defective only in those basement membranes in which the three chains are 
associated within the α3α4α5(IV)-α3α4α5(IV) network.
Expression of mutant collagen type IV results in splitting of the GBM, podocyte effacement, 
glomerulosclerosis, kidney fibrosis, and ESRD progression.
Men who are hemizygous for mutations in COL4A5 causing X-linked AS have similar clinical 
presentation and prognosis to individuals homozygous for COL4A3 and COL4A4 mutations 
causing autosomal recessive AS. The median age of ESRD onset in untreated male patients 
with X-linked AS has been reported to be 22 years (range 7–39 years) [37, 38]. But, owing 
to imprinting (random inactivation on the two X chromosomes in female individuals) [39], 
female carriers of COL4A5 mutations causing X-linked AS may have a higher risk of ESRD 
than do individuals who are heterozygous for autosomal recessive mutations in COL4A3 and 
COL4A4.
2.3. Clinical presentation of Alport syndrome
The diagnosis of AS should be suspected in patients with family glomerular hematuria and 
with family history of renal failure. Children with AS syndrome can usually be diagnosed 
with mild hematuria with or no episodic macrohematuria and low-grade proteinuria. As the 
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disease progresses, patients gradually develop severe proteinuria and progressive renal fail-
ure. Irrespective of the mode of inheritance of the disorder, proteinuria indicates an increased 
risk of progressive renal disease, even in heterozygous carriers. Changes in the GBM that 
are pathognomonic for AS include splitting and enlargement of the GBM and podocyte 
effacement.
There are several clinical stages in the development of glomerulopathy in AS:
Stage 0: microscopic hematuria (albumin/creatinine rate <30 mg/g/day).
Stage 1: microalbuminuria (albumin/creatinine rate = 30–300 mg/g/day).
Stage 2: gross proteinuria (albumin/creatinine rate >300 mg/g/day).
Stage 3: impaired renal function (glomerular filtration rate <60 ml/min/1.73 m2).
Stage 4: end-stage renal disease.
Diagnosis of AS can be made in most patients after a clinical examination on the basis of the 
typical symptoms including kidney, ear, and eye.
The sensorineural hearing loss in AS, which primarily affects high tones, occurs in 30–50% of 
relatives with renal disease. The severity of auditory and renal features does not correlate. The 
molecular defects that underlie the otopathology in this disease remain poorly understood. 
An animal model of X-linked AS showed complete absence of the α3α4α5 network in the 
inner ear, suggesting that collagen type IV is vital to cochlear function as well as renal func-
tion. The generation of radial tension of the spiral ligament on the basilar membrane via the 
extracellular matrix is necessary for reception of high-frequency sound. The lateral aspect 
of the spiral ligament is populated by tension fibroblasts expressing nonmuscle myosin and 
α-smooth muscle actin [40]. On the basis of the foregoing, it was assumed that in AS, the loss 
of the α3α4α5 network eventually weakens the interaction of fibroblasts with their extracellu-
lar matrix, resulting in reduced tension on the basilar membrane and the inability to respond 
to high-frequency sounds [40]. Findings in Alport mice suggest that the hearing loss may arise 
from dysfunction of the stria vascularis mediated through endothelin-1 [40, 41].
The ocular manifestations in Alport syndrome patients are caused by loss of the collagen IV 
α3α4α5 network in basement membranes of the eyes due to mutations which lead to basement 
membrane thinning, lamellation, and a decrease in its mechanical stability. Most of the ocular 
features in AS do not lead to a visual impairment, but they have diagnostic and prognostic 
value: in some cases, the ocular symptoms suggest the mode of inheritance and the likelihood 
of early-onset renal failure. Such ocular features as central and peripheral retinopathy and 
lenticonus are typical for AS, and their presence confirms the diagnosis.
Anterior lenticonus can be detected in half of men (not women) with X-linked Alport syn-
drome. And its presence is associated with early-onset renal failure. The symptom is often 
found in autosomal recessive AS regardless of the patient’s sex, and therefore, the presence of 
lenticonus in women with AS most likely indicates an autosomal recessive mode of disease 
inheritance [41, 42]. Lenticonus is the consequence of the conical protrusion of the lens anteri-
orly through the thinnest part of the capsule [43]; sometimes, the mechanical weakness of the 
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capsule due to the absence of the α3α4α5 network can lead to its spontaneous ruptures and 
secondary cataract developments [44, 45]. After cataract formation, lenticonus ceases to prog-
ress [46]. Posterior lenticonus is less common in patients with AS. Lenticonus is usually found 
in early middle-age patients with renal failure. The patients complain a progressive difficulty 
in focusing due to of their abnormal lens shape. The presence of an oil droplet sign on direct 
ophthalmoscopy or slit-lamp examination confirms the diagnosis. Visual symptoms progress 
with a time, and most patients eventually require surgery. The treatment for both symptom-
atic lenticonus and cataract includes the lens removal and intraocular lens implantation.
The central or perimacular fleck retinopathy and peripheral coalescing fleck retinopathy are 
common retinal abnormalities in patients with AS. The other retinal changes include mani-
festations of temporal thinning [47, 48]: lamellar and giant macular hole, a lozenge, loss of 
the foveal reflex, disturbances of foveal pigmentation, including a bull’s eye or vitelliform 
maculopathy [48, 49]. Central fleck retinopathy is present in 60% of men and at least 15% 
of women with X-linked AS and 50% of individuals with recessive disease [50]. It is more 
common with early-onset renal failure and lenticonus [47]. The central retinopathy varies 
from scattered whitish-yellow dots and flecks to a dense, almost confluent annulus around 
the region of temporal retinal thinning. The fleck retinopathy is associated with an abnormal 
inner limiting membrane. Thinning of the inner limiting membrane/nerve fiber layer may 
interfere with the nutrition of the overlying cells, removal of debris, and maintenance of the 
watertight barrier. The central retinopathy is best seen with color photographs and red-free 
images centered on the macula. Specialized tests of retinal function, such as electroretinogram 
and electrooculogram, are normal or nearly normal. The peripheral fleck retinopathy is the 
most common retinal abnormality, occurring in most men and 25% of women with X-linked 
AS and most individuals with recessive disease [47, 48]. The asymmetric patches of conflu-
ent flecks are characteristic signs of peripheral retinopathy [50]. The appearance on optical 
coherence tomography (OCT) and fleck location in relation to the blood vessels suggests that 
their formation is related to pathological changes of the retinal pigment epithelium/Bruch’s 
membrane. The peripheral retinopathy is a very important diagnostic and prognostic symp-
tom of AS associated with early-onset renal failure, central retinopathy, and lenticonus. But 
the peripheral retinopathy can also be present in women with X-linked AS who have normal 
renal function [47]. The peripheral retinopathy is best seen on ophthalmic examination or 
with retinal photographs that extend beyond the standard views into the periphery and with 
red-free retinal images. Temporal retinal thinning is very common in men and women with 
X-linked AS, and in patients with recessive disease [41, 42, 47, 48]. The lozenge, dull macular 
reflex, foveopathy, and lamellar and macular holes all affect the temporal retina and reflect 
retinal thinning of both the inner limiting membrane and Bruch’s membrane. Thinning is 
confirmed with retinal thickness measurements on OCT. However, thinning is common in 
all forms of Alport syndrome and less sensitive diagnostically than a peripheral retinopathy. 
Hypopigmentation occurred in Alport syndrome is often not diagnosed. It is usually pres-
ent along with perimacular flecks or other ocular features and does not lead to the visual 
impairment. Severe forms, such as a bull’s eye or vitelliform retinopathy, may be occasion-
ally found. Lamellar, partial-thickness macular holes, and giant macular holes lamellar are 
uncommon in patients with X-linked and autosomal recessive AS. This sign is unspecific for 
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AS. But in AS, the macular holes are larger (giant holes) and occur at a younger age than the 
spontaneous holes in patients who do not have AS. Holes may be asymmetric, unilateral, or 
bilateral. Beginning with multiple small defects, they hollow out from the surface of the inner 
limiting membrane in the consequence of accelerated passage of fluid through the defective 
Bruch’s membrane, and followed by microcysts formation due to membrane breaking [50]. 
Patients with macular holes suffer from metamorphopsia (where straight lines are distorted) 
and impairment of central vision. In some patients, holes only become evident when there is 
no improvement in vision after surgery for lenticonus. Lamellar holes might be overlooked by 
retinal photographs; the OCT is required for their demonstration. Holes in AS do not respond 
well to surgical closure and often lead to a permanent loss of vision.
Posterior polymorphous corneal dystrophy and macular hole are rare but also suggest the 
Alport syndrome. Corneal disease is recognized infrequently in Alport syndrome. Erosions 
result from an abnormal Bowman’s membrane in the corneal subepithelium and posterior 
polymorphous corneal dystrophy from an abnormal Descemet’s membrane in the subendo-
thelium [41]. The affected membranes lack the collagen IV α3α4α5 network, are weak, and 
adhere poorly to the epithelium, endothelium, and underlying stroma. Superficial corneal 
erosions occur in 10% of patients, but they are intermittent and hence. Their onset may precede 
the diagnosis of AS and is often in the late teenage years. They typically occur in individuals 
with early-onset renal failure and other extrarenal features. Posterior polymorphous corneal 
dystrophy is rare and more serious than the corneal erosions. Patients may be asymptom-
atic or have photophobia, watering, and grittiness. The diagnosis is based on high-resolution 
anterior segment OCT, slit-lamp biomicroscopy, specular microscopy, or in vivo confocal 
microscopy: there are multiple clusters of vesicles (“doughnuts”) or bands (“snail tracks”) at 
the posterior corneal surface. The vesicles result from vacuolar degeneration of dying cells or 
multilayered epithelial cell protuberances from Descemet’s membrane. Treatment is usually 
symptomatic; sometimes, the dystrophy progresses, and corneal transplantation is required.
Ocular features are less sensitive but more specific than hearing loss in diagnostic of AS, 
because hearing loss occurs also in other inherited renal diseases and in dialysis patients. 
In addition, ocular symptoms may help distinguish between X-linked and autosomal reces-
sive inheritance. Central retinopathy, lenticonus, and macular hole are rare in women with 
X-linked AS. The presence of any of these futures in a woman with hematuria leads to sus-
pected autosomal recessive AS. Furthermore, revealed peripheral retinopathy in the mother 
of a boy with hematuria indicates the diagnosis of AS and also X-linked inheritance of the 
disease. Some ocular features have a prognostic value because they are associated with early-
onset renal failure. Thus, central retinopathy and lenticonus usually indicate the onset of renal 
failure before the age of 30 years. Therefore, it is important to conduct a thorough ophthal-
mologic examination (slit-lamp examination, retinal photography, and OCT) in assessing 
patients with suspected AS. These tests are acceptable to patients, noninvasive, inexpensive, 
and widely available.
Other features of Alport syndrome include gastroesophageal leiomyomatosis and vascular 
abnormalities. Gastroesophageal leiomyomatosis is a very rare pathology characterized by 
benign nodular tumors with smooth muscle cells origin. The condition clinically presents by 
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dysphagia. Leiomyomatosis can also affect the tracheobronchial tree and the genital tract. 
Leiomyomatosis in AS is a consequence of a large deletion in the COL4A5 and COL4A6 genes, 
which encode collagen α5 (IV) or α5α6 (IV) chains in smooth muscle cells of the gastroesopha-
geal tract [51, 52]. The 𝛼5 and 𝛼6 chains of type IV collagen are also found in the basement 
membranes surrounding vascular smooth muscle cells in the intima and media of aorta and 
other arteries in mice model [53]. Seki et al. [53] believed that 𝛼5 and 𝛼6 chains of type IV 
collagen in the basement membranes may have particular function in the arteries which are 
required to tolerate strong pulse and blood pressure such as the aorta. AS is associated with 
aortic abnormalities including aortic dilatation, ruptured ascending aortic aneurysm, aortic 
dissection, aortic insufficiency, and bicuspid aortic valve and coronary artery pathology 
including spontaneous coronary artery dissection in male patients [54–56].
Furthermore, patients with AS and mitral valve prolapse or ventricular septal defects and 
ruptured intracranial and coronary artery aneurysms have also been described [54, 57]. 
Therefore, the vascular imaging techniques could be included in the examination of patients 
with AS, especially in cases of family history of vascular abnormalities.
2.4. Differential diagnosis of Alport syndrome
In cases where the diagnosis of AS was not confirmed by clinical workup, morphology, or 
genetic test, other diseases with similar symptoms should be considered. A combination of 
kidney pathology and hearing loss can be associated with mutations of gene encoding mito-
chondrial and cytoskeletal proteins, ion channels, and receptors.
Patients with mitochondriopathy associated with mutations in the COQ6 gene develop early-
onset steroid-resistant nephrotic syndrome and sensorineural deafness [58]. The mutation 
leads to deficiency of ubiquinone biosynthesis monooxygenase COQ6 protein, localized in 
the Golgi apparatus of the stria vascularis and glomerular podocytes, and to upregulation of 
proapoptotic factors [58].
Alström syndrome is characterized by a defect of the primary cilium that is caused by muta-
tions in ALMS1 and leads to renal failure, sensorineural deafness in young adulthood, and 
vision loss in adulthood [59].
MYH-9-related disease should be considered in patients presenting with proteinuria and 
thrombocytopenia [60]. MYH-9-related disease (the gene for the heavy chain of nonmuscle 
myosin IIA) is a rare inherited autosomal dominant condition characterized by progressive 
nephritis (39%), macrothrombocytopenia (100%), Dohle-like leukocyte inclusions (100%), 
high-tone sensorineural deafness (49%), and cataract (54%) [60, 61]. Renal disease ranged 
from microscopic hematuria to end-stage renal failure necessitating dialysis and kidney 
transplantation. The most striking difference between hearing loss in MYH-9-related disease 
(or Fechtner syndrome) and that in AS was that the vast majority of hearing disorders in 
the latter occur in male patients. Hearing loss in MYH-9-related disease develops from the 
second decade of life and progresses slowly with several episodes of sudden deafness [60]. 
Renal biopsy findings are consistent with those of AS. Chronic renal failure can occur at a 
young age in patients with MYH-9-related disease.
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A recent report described a COL4A1 frameshift mutation in a family with autosomal domi-
nant hematuria, GBM thinning, kidney cysts, and progressive kidney disease [62, 63]. The 
syndrome is characterized by hereditary angiopathy with retinal tortuosities, aneurysms, 
muscular cramps, and nephropathy manifesting as hematuria or cysts (HANAC). As such, 
investigation of patients with unexplained hematuria should include a search for extrarenal 
symptoms of HANAC, especially retinal abnormalities.
2.5. Renal prognosis
The expected ESRD age is similar for the males with X-linked and patients with autosomal 
recessive AS and comprises 23–25 years [4]. The risk of ESRD development in patients with 
X-linked AS by the age of 20 years is 70% in males, whereas only 5% in females; by the age of 
40 years: 90 and 10%, respectively [19]. For many years, female members of Alport families 
who had hematuria were considered to be carriers who were not at risk for ESRD, despite 
reports of ESRD in female Alport patients. But review of clinical outcomes of nearly 300 girls 
and women with confirmed heterozygous COL4A5 mutations showed that 12 and 30% of 
female have the probability of developing ESRD before the age of 40 and 60 years, respectively 
[19]. The 95% of heterozygous females had hematuria, the 75%—proteinuria; in addition, it 
was found that the proteinuria increased the risk of ESRD.
Patients with heterozygous mutations compared to patients with mutations in both alleles of 
COL4A3 or COL4A4 (autosomal recessive Alport syndrome) or hemizygous mutations in 
COL4A5 (males with X-linked Alport syndrome) usually have milder renal involvement with late 
ESRD development and do not have extrarenal manifestations (ocular changes and hearing loss). 
But, lifetime risk of ESRD in heterozygous patients is higher than in the general population [64].
AS accounted for 0.5% of all cases of ESRD and was found to be associated with superior 
dialysis patient survival, superior posttransplant patient survival, and potentially superior 
renal allograft survival to matched controls with other causes of ESRD [65–67]. An incidence 
rate of anti-GBM antibody disease after kidney transplantation comprises 1–5% [65–67].
2.6. Treatment of Alport syndrome
Early diagnosis of AS is important, since therapeutic blockade of the renin-angiotensin-
aldosterone system can slow the progression to ESRD depending on the stage of the disease 
when therapy is initiated. Angiotensin-converting enzyme (ACE) inhibitors are not a specific 
therapy for AS. The antihypertensive and antiproteinuric properties of ACE inhibitors lead 
to their nephroprotective effect. The animal models of AS have shown a major role of altered 
composition of the GBM and of podocytes (their cytoskeleton and their collagen receptors) 
with activation of profibrotic factors in disease progression [32, 33]. ACE inhibitors seem to be 
able to downregulate profibrotic factors independently from blood pressure and the amount 
of proteinuria in the Alport animal model [68].
The Alport Syndrome Research Collaborative recommends use of ACE inhibitors in all 
affected individuals with microalbuminuria or proteinuria, and underlines the importance of 
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using standardized dosing regimens and monitoring microalbuminuria during the treatment 
[69]. The ACE inhibitor ramipril is recommended as the first-line therapy; in cases of adverse 
effects associated with use of ramipril, the treatment with angiotensin-1-receptor antagonists 
will be recommended [69, 70]. The Alport Syndrome Research Collaborative guidelines sug-
gest, therefore, that therapy with ACE inhibitors can be considered as early as stages 0 and 1 
of the disease [69].
The age at progression from microalbuminuria to proteinuria in children with Alport syn-
drome is an important prognostic marker—the earlier this transition occurs, the worse the 
prognosis [71].
Currently, the only recruiting trial is the prospective, randomized placebo-controlled EARLY 
PRO-TECT Alport trial, enrolling pediatric patients with stages 0 and 1 Alport syndrome [72]. 
The goal of this trial is to clarify whether an early start of therapy delays renal failure more 
effectively than later onset of therapy and, above all, whether therapy in the early stages of 
Alport syndrome is safe. The trial will also investigate a potential protective effect of ramipril 
against the hearing loss as a secondary end point [72]. It seems to be very important because 
currently there are no therapies that can prevent the ocular changes or hearing loss develop-
ment and progression in patients with AS.
Studies in animal models have revealed many potential new therapies for use in Alport 
syndrome: inhibitors of proinflammatory factors (for example, TGF-β1 and MMPs) [73, 74]; 
statins [75]; BX471 (a chemokine receptor-1 blocker) [76]; and upregulation of the expression 
of bone morphogenetic protein 7 [77]. A phase II study of antimicroRNA-21 treatment of 
patients with Alport syndrome 18 years of age or older with glomerular filtration rates of 
45–90 ml/min/1.73 m2 will be start; its primary goal will be determining the glomerular filtra-
tion rate decline during therapy [78]. In transgenic Alport mice, antimicroRNA-21 treatment 
reduced glomerular inflammation and impaired renal fibrotic pathways. A phase II/III study 
of the efficacy and safety of bardoxolone methyl for Alport syndrome patients with chronic 
kidney disease (CARDINAL) has been started [79].
3. Conclusion
Alport syndrome is a multisystem hereditary disorder characterized by progressive renal dis-
ease, sensorineural deafness, and eye abnormalities. Diagnosis of AS can be made on the basis 
of the typical symptoms, renal morphology, and/or genetic tests. Early diagnosis of Alport 
syndrome is very important, since therapeutic blockade of the renin-angiotensin-aldosterone 
system can slow the progression to ESRD.
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